ABIONYX Pharma SA (EPA:ABNX)
France · Delayed Price · Currency is EUR 2.195
-0.045 (-2.01%)
Jun 19, 2026, 5:35 PM CET
ABIONYX Pharma Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, ABIONYX Pharma stock has a consensus rating of "Strong Buy" and an average price target of €10.50. The average 1-year stock price forecast is 378.36% higher than the current stock price, while the lowest is €10.00 (+355.58%) and the highest is €11.00 (+401.14%).
Price Target: €10.50 (+378.36%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ABIONYX Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Financial Forecast
Revenue This Year
4.66M
from 4.06M
Increased by 14.69%
Revenue Next Year
14.72M
from 4.66M
Increased by 215.84%
EPS This Year
-0.47
from -0.16
EPS Next Year
-0.30
from -0.47
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 5.2M | ||
| Avg | 4.7M | ||
| Low | 4.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 28.5% | ||
| Avg | 14.7% | ||
| Low | 0.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.41 | ||
| Avg | -0.47 | ||
| Low | -0.52 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |